Table 2

OR from robust logistic regression analysis testing the association between biomarker levels (baseline and changes from baseline to week 4) and clinical endpoints (ASAS 20 response at week 14, changes from baseline to week 14 in BASFI score and changes from baseline to week 14 in BASDAI score)

	ASAS 20 at week 14		BASFI change from baseline to week 14		BASDAI change from baseline to week 14
Biomarker	OR	p Value	OR	p Value	OR	p Value
Baseline
Apolipoprotein C3	0.35	0.019	0.41	0.036	0.69	NS
Deoxypyridinoline	6.49	0.033	4.15	NS	7.48	0.017
Epithelial neutrophil activating peptide-78	2.00	NS	2.44	0.031	3.12	0.010
Haptoglobin	1.70	0.046	1.72	0.040	1.70	NS
Insulin	0.63	0.009	0.66	0.013	0.77	NS
Interleukin 6	1.80	0.017	1.47	NS	1.72	0.014
Leptin	0.64	0.041	0.62	0.027	0.79	NS
N-terminal propeptide of type 1 collagen	5.94	0.004	4.20	0.011	2.47	0.049
Osteocalcin	10.88	0.001	10.14	0.002	3.13	0.033
Change from baseline to week 4
α-1 Antitrypsin	0.04	0.018	0.09	0.039	0.09	0.032
C-reactive protein	0.72	0.025	0.69	0.010	0.74	0.025
Complement 3	0.02	0.004	0.02	0.003	0.01	0.001
Haptoglobin	0.20	0.007	0.23	0.006	0.17	0.002
Interleukin 6	0.36	0.003	0.52	0.013	0.43	0.002
Serum amyloid P	0.30	NS	0.13	0.013	0.21	0.036
Thyroxine binding globulin	0.33	NS	0.07	0.027	0.09	0.032

Only biomarkers with significant associations across multiple endpoints are shown.
OR represents the increased odds of clinical response for a 1 unit change on the log₂ scale or a doubling on the linear scale.
ASAS 20, at least 20% improvement in Assessment in SpondyloArthritis international Society response criteria; Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; NS, not significant (p>0.05).